Nothing Special   »   [go: up one dir, main page]

EA201591738A1 - Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы - Google Patents

Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы

Info

Publication number
EA201591738A1
EA201591738A1 EA201591738A EA201591738A EA201591738A1 EA 201591738 A1 EA201591738 A1 EA 201591738A1 EA 201591738 A EA201591738 A EA 201591738A EA 201591738 A EA201591738 A EA 201591738A EA 201591738 A1 EA201591738 A1 EA 201591738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
functional
ret
disorders
constipation
Prior art date
Application number
EA201591738A
Other languages
English (en)
Other versions
EA029296B1 (ru
Inventor
Хилари Шенк Эйдам
Майкл П. Демартино
Чжень Гун
Ами Хойпин Гуань
Каушик Раха
Чэньдэ У
Хайин Ян
Хайюй Юй
Чжилю Чжан
Муй Чэунг
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201591738A1 publication Critical patent/EA201591738A1/ru
Publication of EA029296B1 publication Critical patent/EA029296B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к новым соединениям, которые являются ингибиторами реаранжированной в процессе трансфекции (RET) киназы, к содержащим их фармацвтическим композициям, к способам их получения и к их применению в терапии, отдельно или в комбинации, для нормализации чувствительности, подвижности и/или секреции желудочно-кишечного тракта или и/или расстройств или заболеваний брюшной полости и/или лечения заболеваний, связанных с дисфункцией RET, или где модуляция RET активности может иметь терапевтический эффект, включая, но не ограничиваясь этим, все классификации синдрома раздраженной толстой кишки (IBS), включая тип дефекации с преобладанием диареи, с преобладанием запора или чередующийся тип, функциональное вздутие живота, функциональный запор, функциональную диарею, неопределенное функциональное расстройство кишечника, функциональный абдоминальный болевой синдром, хронический идиопатический запор, функциональные расстройства пищевода, функциональные гастродуоденальные расстройства, функциональную аноректальную боль, воспалительное заболевание кишечника, пролиферативные заболевания, такие как немелкоклеточный рак легкого, гепатоцеллюлярная карцинома, рак прямой кишки, медуллярный рак щитовидной железы, фолликулярный рак щитовидной железы, анапластический рак щитовидной железы, папиллярный рак щитовидной железы, опухоли головного мозга, рак брюшной полости, солидные опухоли, другие виды рака легких, рак головы и шеи, глиомы, нейробластомы, синдром Фон Гиппеля-Линдау и злокачественные опухоли почек, рак молочной железы, рак фаллопиевых труб, рак яичников, переходно-клеточный рак, рак предстательной
EA201591738A 2013-03-15 2014-03-14 Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы EA029296B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013072683 2013-03-15
CN2013090059 2013-12-20
CN2014072449 2014-02-24
PCT/IB2014/059817 WO2014141187A1 (en) 2013-03-15 2014-03-14 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201591738A1 true EA201591738A1 (ru) 2016-01-29
EA029296B1 EA029296B1 (ru) 2018-03-30

Family

ID=50390154

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591738A EA029296B1 (ru) 2013-03-15 2014-03-14 Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы

Country Status (33)

Country Link
US (2) US9382238B2 (ru)
EP (1) EP2970191B1 (ru)
JP (1) JP2016516026A (ru)
CN (1) CN105051027A (ru)
AU (1) AU2014229233B2 (ru)
BR (1) BR112015023618A2 (ru)
CA (1) CA2905627A1 (ru)
CL (1) CL2015002514A1 (ru)
CR (1) CR20150490A (ru)
CY (1) CY1118730T1 (ru)
DK (1) DK2970191T3 (ru)
DO (1) DOP2015000244A (ru)
EA (1) EA029296B1 (ru)
ES (1) ES2616655T3 (ru)
HR (1) HRP20170363T1 (ru)
HU (1) HUE033423T2 (ru)
IL (1) IL241161A0 (ru)
LT (1) LT2970191T (ru)
ME (1) ME02664B (ru)
MX (1) MX2015012286A (ru)
NZ (1) NZ628388A (ru)
PE (1) PE20151538A1 (ru)
PH (1) PH12015502044A1 (ru)
PL (1) PL2970191T3 (ru)
PT (1) PT2970191T (ru)
RS (1) RS55710B1 (ru)
SG (1) SG11201506695UA (ru)
SI (1) SI2970191T1 (ru)
SM (1) SMT201700152T1 (ru)
TW (1) TW201524958A (ru)
UA (1) UA115264C2 (ru)
UY (1) UY35465A (ru)
WO (1) WO2014141187A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP3191480A1 (en) * 2014-09-08 2017-07-19 GlaxoSmithKline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
JP6538153B2 (ja) 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Rearranged during transfection(ret)阻害剤としての新規な化合物
SI3191450T1 (sl) 2014-09-10 2019-07-31 Glaxosmithkline Intellectual Property Development Limited Piridonski derivati kot preurejeni med transfekcijo (RET) inhibitorjev kinaze
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HUE064659T2 (hu) * 2015-11-02 2024-04-28 Blueprint Medicines Corp RET inhibitorai
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
EP3430005B1 (en) * 2016-03-16 2021-12-08 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ret之抑制劑
BR112018073300A2 (pt) 2016-05-13 2019-03-26 Instituto De Medicina Molecular métodos para tratamento de doenças associadas com as células ilc3
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018213329A1 (en) 2017-05-15 2018-11-22 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
TW202410896A (zh) * 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
EP4353317A3 (en) 2018-04-03 2024-05-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN109096264B (zh) * 2018-08-28 2019-08-23 山东理工职业学院 Ret抑制剂及其制备方法、组合物和用途
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
WO2021164742A1 (zh) * 2020-02-20 2021-08-26 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
TWI777509B (zh) 2020-04-27 2022-09-11 美商美國禮來大藥廠 用於抑制ret激酶之化合物
WO2022017524A1 (zh) * 2020-07-23 2022-01-27 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
MX2023005289A (es) 2020-11-06 2023-07-26 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa.
WO2022254255A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommerchampalimaud E Dr. Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN115626880B (zh) * 2022-11-15 2023-11-14 常州大学 3-硝基-5-氰基三氟甲苯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002422A3 (cs) 1999-08-12 2002-11-13 Pharmacia Italia S. P. A. 3(5)-Aminopyrazolové deriváty, způsob jejich přípravy a jejich pouľití jako protinádorová činidla
MXPA03004644A (es) * 2000-11-27 2003-09-05 Pharmacia Italia Spa Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
KR20090064602A (ko) * 2006-10-16 2009-06-19 노파르티스 아게 단백질 키나제 억제제로서 유용한 페닐아세트아미드
EP3048099A3 (en) * 2006-11-15 2016-09-21 YM BioSciences Australia Pty Ltd Inhibitors of kinase activity
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors

Also Published As

Publication number Publication date
JP2016516026A (ja) 2016-06-02
DK2970191T3 (en) 2017-03-20
HRP20170363T1 (hr) 2017-04-21
WO2014141187A1 (en) 2014-09-18
PE20151538A1 (es) 2015-11-18
UY35465A (es) 2014-10-31
US20160271123A1 (en) 2016-09-22
CN105051027A (zh) 2015-11-11
LT2970191T (lt) 2017-03-10
TW201524958A (zh) 2015-07-01
SG11201506695UA (en) 2015-09-29
SI2970191T1 (sl) 2017-04-26
HUE033423T2 (en) 2017-11-28
IL241161A0 (en) 2015-11-30
PL2970191T3 (pl) 2017-07-31
PH12015502044A1 (en) 2016-01-18
NZ628388A (en) 2016-09-30
AU2014229233B2 (en) 2016-08-11
US9789100B2 (en) 2017-10-17
MX2015012286A (es) 2016-05-31
EA029296B1 (ru) 2018-03-30
SMT201700152T1 (it) 2017-05-08
ES2616655T3 (es) 2017-06-13
UA115264C2 (uk) 2017-10-10
CR20150490A (es) 2015-11-20
CY1118730T1 (el) 2017-07-12
CA2905627A1 (en) 2014-09-18
BR112015023618A2 (pt) 2017-07-18
DOP2015000244A (es) 2015-12-31
CL2015002514A1 (es) 2016-02-05
EP2970191A1 (en) 2016-01-20
RS55710B1 (sr) 2017-07-31
PT2970191T (pt) 2017-03-23
US20160002215A1 (en) 2016-01-07
ME02664B (me) 2017-06-20
AU2014229233A1 (en) 2015-09-24
US9382238B2 (en) 2016-07-05
EP2970191B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
EA201591738A1 (ru) Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы
PH12017500454A1 (en) Novel compounds as rearranged during transfection (ret) inhibitors
PH12017500425A1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
AR095308A1 (es) Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
EA201992418A1 (ru) Бициклические соединения и их применение в лечении рака
JP2017514806A5 (ru)
EA201792304A1 (ru) Комбинированная терапия для лечения рака
MY195488A (en) Protein Kinase C Inhibitors and Methods of Their use
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
AR101801A1 (es) Compuestos de benzamida y acetamida, sales farmacéuticamente aceptables de los mismos, composición farmacéutica que los comprende y su uso para la preparación de un medicamento
TH158993A (th) อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret)
TH1701001252A (th) อนุพันธ์ไพริดีนในฐานะที่เป็นตัวยับยั้งรีอาร์เรนจ์ดดิวริงทรานสเฟคชัน (ret)
EA202091908A2 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA202090841A3 (ru) Связывающиеся с egfr и c-met молекулы с доменами фибронектина типа iii

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU